


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華控康泰集團有限公司

Kontafarma China Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

CHANGE OF EXECUTIVE DIRECTOR AND CHAIRMAN

RESIGNATION OF EXECUTIVE DIRECTOR, CHAIRMAN AND PRESIDENT AND CESSATION OF MEMBER OF BOARD COMMITTEES

The board (the “**Board**”) of directors (the “**Directors**”) of Kontafarma China Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Wang Feifei (王飛飛先生) has tendered his resignation as an executive Director of the Company, the chairman of the Board and the president of the Group with effect from 8 May 2026 since he has to pursue his other work commitments.

Following the resignation of Mr. Wang Feifei, he also ceased to be the chairman of each of the executive committee (the “**Executive Committee**”), the nomination committee (the “**Nomination Committee**”), the share dealing committee (the “**Share Dealing Committee**”) and the investment committee of the Company (the “**Investment Committee**”). Mr. Wang Feifei has confirmed to the Board that he has no disagreement with the Board or the Company and that there is no other matter in respect of his resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to extend its appreciation to Mr. Wang Feifei for his valuable contribution during his tenure of office in the Company.

APPOINTMENT OF EXECUTIVE DIRECTOR, CHAIRMAN AND PRESIDENT

The Board hereby announces that Mr. Wang Limin (王利民先生) has been appointed as an executive Director of the Company, the chairman of the Board and the president of the Group as well as the chairman of each of the Executive Committee, the Nomination Committee, the Share Dealing Committee and the Investment Committee with effect from 8 May 2026.

The biographical details of Mr. Wang Limin are set out as follows:

Mr. Wang Limin, aged 51, has been appointed as deputy general manager of Shanxi Construction Investment Group Co., Ltd. (“**Shanxi Construction**”), the chairman of Shenzhen Warranty Asset Management Co., Ltd.* (深圳市華融泰資產管理有限公司) and Jinjiantou South China Investment & Construction Co., Ltd.* (晉建投華南投資建設有限公司), and general manager of South China regional headquarters of Shanxi Construction since May 2025. He was the chairman of the board of directors and executive director of Shanxi Installation Group Co., Ltd. (山西省安裝集團股份有限公司)(“**Shanxi Installation**”), a H-share company listed on the Main Board of the Stock Exchange (stock code: 2520) from March 2022 to 22 May 2025. He was also the chairman of the nomination committee of Shanxi Installation. Mr. Wang Limin was responsible for leading the board of directors of Shanxi Installation and he was also in charge of its audit and risk control department during his stay there. Mr. Wang Limin was appointed as a director of Shanxi Installation in 2018 prior to his redesignation as an executive director in March 2022 there.

Mr. Wang Limin joined Shanghai branch of Shanxi Installation group in October 1994 initially as an installation worker and worked his way to be the deputy manager of the Shanghai branch in February 2004. In March 2011, Mr. Wang Limin took the role of head of engineering department of Shanxi Installation group. Mr. Wang Limin became the head of the safety production department of Shanxi Installation group in March 2014 and was promoted to be deputy chief engineer, and the executive deputy general manager of East China regional branch, of Shanxi Installation group in June 2014. He was further promoted to be deputy general manager of Shanxi Installation group in April 2016 and subsequently became deputy secretary of the Communist Party Committee of Shanxi Installation and its general manager in March 2018. Mr. Wang Limin had been the secretary of Communist Party Committee of Shanxi Installation since November 2020 during his stay there.

In January 2010, Mr. Wang Limin obtained a bachelor’s degree in Electronic Engineering and Automation from Tongji University through correspondence courses and a bachelor’s degree in Water Supply and Drainage Engineering from Jiangnan University also through correspondence courses. In June 2020, he obtained a master’s degree in Business Administration from Shanxi University of Finance and Economics.

Mr. Wang Limin was recognized as a constructor in electromechanical installation by the Ministry of Construction of the People’s Republic of China in March 2008, and a senior engineer in water supply and drainage engineering by the Human Resources and Social Security Bureau of Shanxi Province in December 2019.

Mr. Wang Limin received the special honor certificate as the leader of engineering (contractor) enterprise winning 2019–2020 China Excellent Installation Project Award (China Installation Star) (2019–2020年度中國安裝工程優質獎(中國安裝之星)工程企業領導人(承建)特別榮譽證書) from China Installation Association (中國安裝協會) and was named the 2020 National Excellent Integrity Entrepreneur (2020年度全國優秀誠信企業

家) by Commercial Credit Center (商業信用中心) and “Enterprise Management” Magazine Publisher (《企業管理》雜誌社). Mr. Wang Limin was honored the title of “Model Worker of the National Housing and Urban-Rural Development System (全國住房和城鄉建設系統勞動模範)” by the Department of Human Resources and Social Security and the Ministry of Housing and Urban-Rural Development in December 2022. He was appointed as a cadre of the Organization Department of the Shanxi Provincial Committee of the Communist Party of the People’s Republic of China in October 2023 and July 2024, respectively.

Mr. Wang Limin entered into a service contract with the Company as an executive Director, the chairman of the Board and the president of the Group on 8 May 2026. There was no fixed term as to his appointment as an executive Director subject to the requirements for retirement by rotation and re-election in accordance with the memorandum and articles of association of the Company. Pursuant to the service contract, Mr. Wang Limin agrees to waive his entitlement to any Director’s fee from the Company as an executive Director.

Save as disclosed above, as at the date of this announcement, Mr. Wang Limin (i) does not hold any other positions with the Company or its subsidiaries; (ii) does not have any other major appointments and professional qualifications; (iii) does not have any relationship with any other Directors, senior management, substantial Shareholders (as defined under the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) or controlling Shareholders (as defined under the Listing Rules) of the Company; (iv) is not interested in the shares of the Company as defined in Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (v) does not hold any directorships in any listed public companies in Hong Kong or overseas in the past three years.

Save for the information set out above, there is no other information which is discloseable pursuant to any requirements set out in Rules 13.51(2)(h) to (v) of the Listing Rules, and there are no other matters that need to be brought to the attention of the Shareholders in relation to the appointment of Mr. Wang Limin.

The Board would like to express its warm welcome to Mr. Wang Limin for joining the Board.

By order of the Board of
Kontafarma China Holdings Limited
Wang Limin
Chairman

Hong Kong, 8 May 2026

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Wang Limin (Chairman and President), Mr. Ge Shouwen (Vice President), and Ms. Guo Zixiu (Financial Controller); one non-executive Director, namely Mr. Huang Yu; and three independent non-executive Directors, namely Dr. Tang Lai Wah, Dr. Ho Ho Ming and Mr. Yao Xiaomin.

** For identification purposes only*